Stratification of non-small cell lung adenocarcinoma patients with EGFR actionable mutations based on drug-resistant stem cell genes

EGFR-TKIs were used in NSCLC patients with actionable EGFR mutations and prolong prognosis. However, most patients treated with EGFR-TKIs developed resistance within around one year. This suggests that residual EGFR-TKIs resistant cells may eventually lead to relapse. Predicting resistance risk in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Xiaohong, Li, Lifeng, Xie, Liang, Liu, Zhentian, Zhang, Guoliang, Gao, Xuan, Peng, Wenying, Deng, Haiyi, Yang, Yilin, Yang, Meiling, Chang, Lianpeng, Yi, Xin, Xia, Xuefeng, He, Zhiyi, Zhou, Chengzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241979/
https://www.ncbi.nlm.nih.gov/pubmed/37288343
http://dx.doi.org/10.1016/j.isci.2023.106584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241979/
https://www.ncbi.nlm.nih.gov/pubmed/37288343
http://dx.doi.org/10.1016/j.isci.2023.106584

Ejemplares similares